Risk assessment of tuberculosis in immunocompromised patients. A TBNET study.

RATIONALE In the absence of active tuberculosis, a positive tuberculin skin test (TST) or interferon-γ release assay (IGRA) result defines latent infection with Mycobacterium tuberculosis, although test results may vary depending on immunodeficiency. OBJECTIVES This study compared the performance of TST and IGRAs in five different groups of immunocompromised patients, and evaluated their ability to identify those at risk for development of tuberculosis. METHODS Immunocompromised patients with HIV infection, chronic renal failure, rheumatoid arthritis, solid-organ or stem-cell transplantation, and healthy control subjects were evaluated head-to-head by the TST, QuantiFERON-TB-Gold in-tube test (ELISA), and T-SPOT.TB test (enzyme-linked immunospot) at 17 centers in 11 European countries. Development of tuberculosis was assessed during follow-up. MEASUREMENTS AND MAIN RESULTS Frequencies of positive test results varied from 8.7 to 15.9% in HIV infection (n = 768), 25.3 to 30.6% in chronic renal failure (n = 270), 25.0% to 37.2% in rheumatoid arthritis (n = 199), 9.0 to 20.0% in solid-organ transplant recipients (n = 197), 0% to 5.8% in stem-cell transplant recipients (n = 103), and 11.2 to 15.2% in immunocompetent control subjects (n = 211). Eleven patients (10 with HIV infection and one solid-organ transplant recipient) developed tuberculosis during a median follow-up of 1.8 (interquartile range, 0.2-3.0) years. Six of the 11 patients had a negative or indeterminate test result in all three tests at the time of screening. Tuberculosis incidence was generally low, but higher in HIV-infected individuals with a positive TST (3.25 cases per 100 person-years) than with a positive ELISA (1.31 cases per 100 person-years) or enzyme-linked immunospot result (1.78 cases per 100 person-years). No cases of tuberculosis occurred in patients who received preventive chemotherapy. CONCLUSIONS Among immunocompromised patients evaluated in this study, progression toward tuberculosis was highest in HIV-infected individuals and was poorly predicted by TST or IGRAs. Clinical trial registered with www.clinicaltrials.gov (NCT 00707317).

[1]  P. Ravn,et al.  6-year follow-up of 522 HIV-positive individuals screened for Mycobacterium tuberculosis infection in Denmark , 2014, European Respiratory Journal.

[2]  L. Fiebig,et al.  Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors , 2014, BMC Infectious Diseases.

[3]  J. Janssens,et al.  Contribution of Interferon-&ggr; Release Assays (IGRAs) to the Diagnosis of Latent Tuberculosis Infection After Renal Transplantation , 2013, Transplantation.

[4]  F. van Leth,et al.  Risk of Tuberculosis after Antiretroviral Treatment Initiation: A Comparison between Efavirenz and Nevirapine Using Inverse Probability Weighting , 2013, Antiviral therapy.

[5]  C. Chee,et al.  Diagnosis and treatment of latent infection with Mycobacterium tuberculosis , 2013, Respirology.

[6]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[7]  M. Sester.  Tuberculosis in the immunocompromised host , 2013 .

[8]  S. Wie,et al.  Predictive value of interferon-γ ELISPOT assay in HIV 1-infected patients in an intermediate tuberculosis-endemic area. , 2012, AIDS research and human retroviruses.

[9]  T. Shim,et al.  Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[10]  R. Diel,et al.  Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. , 2012, Chest.

[11]  M. Ison,et al.  The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement , 2012, European Respiratory Journal.

[12]  C. Olsen,et al.  Discordance among commercially available diagnostics for latent tuberculosis infection. , 2012, American journal of respiratory and critical care medicine.

[13]  Hsin-Hua Chen,et al.  Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay , 2011, Annals of the rheumatic diseases.

[14]  M. Pai,et al.  Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[15]  S. Choi,et al.  A Prospective Longitudinal Study Evaluating the Usefulness of a T‐Cell‐Based Assay for Latent Tuberculosis Infection in Kidney Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  E. Rubin,et al.  Clinical practice. Latent tuberculosis infection in the United States. , 2011, The New England journal of medicine.

[17]  W. Haas,et al.  Tuberculosis contact investigation in low prevalence countries: a European consensus , 2010, European Respiratory Journal.

[18]  R. Diel,et al.  Interferon-&ggr; release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis , 2010, European Respiratory Journal.

[19]  J. Kaldor,et al.  Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[20]  N. Inanç,et al.  Agreement Between Quantiferon-TB Gold Test and Tuberculin Skin Test in the Identification of Latent Tuberculosis Infection in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis , 2009, The Journal of Rheumatology.

[21]  M. Ernst,et al.  Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection , 2009, European Respiratory Journal.

[22]  T. Rochat,et al.  Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  F. Cobelens,et al.  LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement , 2009, European Respiratory Journal.

[24]  H. Schäfers,et al.  Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs , 2009, European Respiratory Journal.

[25]  A. Rieger,et al.  Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  M. Cerinic,et al.  QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases , 2009, European Respiratory Journal.

[27]  N. Range,et al.  The Impact of HIV Infection and CD4 Cell Count on the Performance of an Interferon Gamma Release Assay in Patients with Pulmonary Tuberculosis , 2009, PloS one.

[28]  M. Dougados,et al.  Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate , 2008, Annals of the rheumatic diseases.

[29]  K. Winthrop,et al.  Interferon-gamma release assays for diagnosing mycobacterium tuberculosis infection in renal dialysis patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[30]  E. Acevedo-Vásquez,et al.  Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. , 2008, The Journal of rheumatology.

[31]  S. Abramson,et al.  Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. , 2008, The Journal of rheumatology.

[32]  O. Manuel,et al.  Comparison of Quantiferon‐TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[33]  Jeffrey N. Martin,et al.  Comparison of an Interferon-γ Release Assay with Tuberculin Skin Testing in HIV-infected Individuals , 2007 .

[34]  K. Khan,et al.  Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[35]  Jeffrey N. Martin,et al.  Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. , 2007, American journal of respiratory and critical care medicine.

[36]  R. Weber,et al.  Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  P. Ravn,et al.  Latent Tuberculosis in HIV positive, diagnosed by the M. Tuberculosis Specific Interferon-γ test , 2006, Respiratory research.

[38]  S. Lawn,et al.  Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort , 2005, AIDS.

[39]  Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. , 1987, MMWR supplements.

[40]  Iuat.  Efficacy of various duration of isoniazid preventive therapy for tuberculosis : five years follow-up in the IUAT trial , 1982 .

[41]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[42]  G. Comstock,et al.  Tuberculosis morbidity in the U.S. Navy: its distribution and decline. , 2015, The American review of respiratory disease.

[43]  W. G. Cochran.  The comparison of percentages in matched samples. , 1950, Biometrika.